Recombinant|recombinant|JJ|O human|human|JJ|O serum|serum|NN|GENE amyloid|amyloid|NN|GENE P|P|NN|GENE in|in|IN|O healthy|healthy|JJ|O volunteers|volunteer|NNS|O and|and|CC|O patients|patient|NNS|O with|with|IN|O pulmonary|pulmonary|JJ|O fibrosis|fibrosis|NN|O .|.|.|O 
PRM-151|PRM-151|NN|O ,|,|,|O recombinant|recombinant|JJ|O human|human|JJ|O Pentraxin-2|Pentraxin-2|NN|GENE (|(|(|O PTX-2|PTX-2|NN|GENE )|)|)|O also|also|RB|O referred|refer|VBD|O to|to|TO|O as|as|IN|O serum|serum|NN|GENE amyloid|amyloid|NN|GENE P|P|NN|GENE (|(|(|O SAP|sap|NN|GENE )|)|)|O ,|,|,|O is|be|VBZ|O under|under|IN|O development|development|NN|O for|for|IN|O treatment|treatment|NN|O of|of|IN|O fibrosis|fibrosis|NN|O .|.|.|O 
A|a|DT|O First-in-Human|First-in-Human|NN|O (|(|(|O FIH|FIH|NN|O )|)|)|O trial|trial|NN|O was|be|VBD|O performed|perform|VBN|O to|to|TO|O assess|assess|VB|O the|the|DT|O safety|safety|NN|O ,|,|,|O tolerability|tolerability|NN|O ,|,|,|O and|and|CC|O pharmacokinetics|pharmacokinetic|NNS|O of|of|IN|O single|single|JJ|O ascending|ascend|VBG|O intravenous|intravenous|JJ|O doses|dose|NNS|O of|of|IN|O PRM-151|PRM-151|NN|O administered|administer|VBN|O to|to|TO|O healthy|healthy|JJ|O subjects|subject|NNS|O ,|,|,|O using|use|VBG|O a|a|DT|O randomized|randomize|VBN|O ,|,|,|O blinded|blind|VBN|O ,|,|,|O placebo|placebo|NN|O controlled|controlled|JJ|O study|study|NN|O design|design|NN|O .|.|.|O 
Each|each|DT|O cohort|cohort|NN|O included|include|VBD|O three|three|CD|O healthy|healthy|JJ|O subjects|subject|NNS|O (|(|(|O PRM-151|PRM-151|NN|O :|:|:|O placebo|placebo|NN|O ;|;|:|O 2:1|2:1|CD|O )|)|)|O .|.|.|O 
SAP|sap|NN|GENE levels|level|NNS|O were|be|VBD|O assessed|assess|VBN|O using|use|VBG|O a|a|DT|O validated|validate|VBN|O ELISA|elisa|NN|O method|method|NN|O ,|,|,|O non-discriminating|non-discriminating|JJ|O between|between|IN|O endogenous|endogenous|JJ|O and|and|CC|O exogenous|exogenous|JJ|O SAP|sap|NN|GENE .|.|.|O 
At|at|IN|O a|a|DT|O dose|dose|NN|O level|level|NN|O of|of|IN|O 10|10|CD|O mg/kg|mg/kg|NN|O ,|,|,|O at|at|IN|O which|which|WDT|O a|a|DT|O physiologic|physiologic|JJ|O plasma|plasma|NN|O level|level|NN|O of|of|IN|O SAP|sap|NN|GENE was|be|VBD|O reached|reach|VBN|O ,|,|,|O two|two|CD|O additional|additional|JJ|O healthy|healthy|JJ|O volunteers|volunteer|NNS|O and|and|CC|O three|three|CD|O pulmonary|pulmonary|JJ|O fibrosis|fibrosis|NN|O (|(|(|O PF|pf|NN|O )|)|)|O patients|patient|NNS|O were|be|VBD|O enrolled|enrol|VBN|O enabling|enable|VBG|O comparison|comparison|NN|O of|of|IN|O the|the|DT|O pharmacokinetic|pharmacokinetic|JJ|O SAP|sap|NN|GENE profile|profile|NN|O between|between|IN|O healthy|healthy|JJ|O volunteers|volunteer|NNS|O and|and|CC|O PF|pf|NN|O patients|patient|NNS|O .|.|.|O 
In|in|IN|O addition|addition|NN|O ,|,|,|O the|the|DT|O percentage|percentage|NN|O of|of|IN|O fibrocytes|fibrocyte|NNS|O (|(|(|O CD45|CD45|NN|O +|+|CC|O /|/|:|O Procollagen-1|Procollagen-1|NN|O +|+|CC|O cells|cell|NNS|O )|)|)|O in|in|IN|O whole|whole|JJ|O blood|blood|NN|O samples|sample|NNS|O was|be|VBD|O assessed|assess|VBN|O to|to|TO|O demonstrate|demonstrate|VB|O biological|biological|JJ|O activity|activity|NN|O of|of|IN|O PRM-151|PRM-151|NN|O in|in|IN|O the|the|DT|O target|target|NN|O population|population|NN|O .|.|.|O 
PRM-151|PRM-151|NN|O administration|administration|NN|O was|be|VBD|O generally|general|RB|O well|well|RB|O tolerated|tolerate|VBN|O .|.|.|O 
In|in|IN|O two|two|CD|O pulmonary|pulmonary|JJ|O fibrosis|fibrosis|NN|O patients|patient|NNS|O non-specific|non-specific|JJ|O ,|,|,|O transient|transient|JJ|O skin|skin|NN|O reactions|reaction|NNS|O (|(|(|O urticaria|urticaria|NN|O and|and|CC|O erythema|erythema|NN|O )|)|)|O were|be|VBD|O observed|observe|VBN|O .|.|.|O 
PRM-151|PRM-151|NN|O administration|administration|NN|O resulted|result|VBD|O in|in|IN|O a|a|DT|O 6-to|6-to|JJ|O 13-fold|13-fold|RB|O increase|increase|VB|O in|in|IN|O mean|mean|JJ|O baseline|baseline|NN|O plasma|plasma|NN|O SAP|sap|NN|GENE levels|level|NNS|O at|at|IN|O dose|dose|NN|O levels|level|NNS|O of|of|IN|O 5|5|CD|O ,|,|,|O 10|10|CD|O ,|,|,|O and|and|CC|O 20|20|CD|O mg/kg|mg/kg|NN|O .|.|.|O 
The|the|DT|O estimated|estimate|VBN|O t1/2|t1/2|NN|O of|of|IN|O PRM-151|PRM-151|NN|O in|in|IN|O healthy|healthy|JJ|O volunteers|volunteer|NNS|O was|be|VBD|O 30|30|CD|O h.|H.|NN|O Pharmacokinetic|pharmacokinetic|JJ|O profiles|profile|NNS|O were|be|VBD|O comparable|comparable|JJ|O between|between|IN|O healthy|healthy|JJ|O volunteers|volunteer|NNS|O and|and|CC|O PF|pf|NN|O patients|patient|NNS|O .|.|.|O 
PRM-151|PRM-151|NN|O administration|administration|NN|O resulted|result|VBD|O in|in|IN|O a|a|DT|O 30-50|30-50|CD|O %|%|NN|O decrease|decrease|NN|O in|in|IN|O fibrocyte|fibrocyte|JJ|O numbers|number|NNS|O 24|24|CD|O h|h|NN|O post-dose|post-dose|NN|O .|.|.|O 
This|this|DT|O suggests|suggest|VBZ|O that|that|IN|O administration|administration|NN|O of|of|IN|O PRM-151|PRM-151|NN|O may|may|MD|O be|be|VB|O associated|associate|VBN|O with|with|IN|O a|a|DT|O reduction|reduction|NN|O of|of|IN|O fibrocytes|fibrocyte|NNS|O in|in|IN|O PF|pf|NN|O patients|patient|NNS|O ,|,|,|O a|a|DT|O population|population|NN|O for|for|IN|O which|which|WDT|O current|current|JJ|O pharmacotherapeutic|pharmacotherapeutic|JJ|O options|option|NNS|O are|be|VBP|O limited|limit|VBN|O .|.|.|O 
The|the|DT|O pharmacological|pharmacological|JJ|O action|action|NN|O of|of|IN|O PRM-151|PRM-151|NN|O should|shall|MD|O be|be|VB|O confirmed|confirm|VBN|O in|in|IN|O future|future|JJ|O research|research|NN|O .|.|.|O 
